

Cover Story
Free
An NCI-sponsored trial showed that up to 70 percent of women with hormone receptor-positive, HER2-negative, axillary lymph node-negative breast cancer would not benefit from chemotherapy.
In Brief
Funding Opportunities
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- Unlocking the future of precision medicine:
The untapped power of RNA - Biden’s diagnosis is unfortunate but—statistically—not surprising
Of the 384 men serving in Congress, 48 are likely to be diagnosed with prostate cancer in their lifetime - Former Maryland Governor Larry Hogan to receive Public Service Leadership Award from National Coalition for Cancer Survivorship
- A new AI tool enables speedy use of ASCO guidelines, eliminating typical errors
- An opportunity for Trump: Position U.S. cancer science to lead the world